These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 9083477)

  • 1. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
    Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
    J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
    Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
    J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereoisomers of cyclic urea HIV-1 protease inhibitors: synthesis and binding affinities.
    Kaltenbach RF; Nugiel DA; Lam PY; Klabe RM; Seitz SP
    J Med Chem; 1998 Dec; 41(25):5113-7. PubMed ID: 9836627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel, picomolar inhibitor of human immunodeficiency virus type 1 protease.
    Sham HL; Zhao C; Stewart KD; Betebenner DA; Lin S; Park CH; Kong XP; Rosenbrook W; Herrin T; Madigan D; Vasavanonda S; Lyons N; Molla A; Saldivar A; Marsh KC; McDonald E; Wideburg NE; Denissen JF; Robins T; Kempf DJ; Plattner JJ; Norbeck DW
    J Med Chem; 1996 Jan; 39(2):392-7. PubMed ID: 8558507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved P1/P1' substituents for cyclic urea based HIV-1 protease inhibitors: synthesis, structure-activity relationship, and X-ray crystal structure analysis.
    Nugiel DA; Jacobs K; Cornelius L; Chang CH; Jadhav PK; Holler ER; Klabe RM; Bacheler LT; Cordova B; Garber S; Reid C; Logue KA; Gorey-Feret LJ; Lam GN; Erickson-Viitanen S; Seitz SP
    J Med Chem; 1997 May; 40(10):1465-74. PubMed ID: 9154969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic sulfamide HIV-1 protease inhibitors, with sidechains spanning from P2/P2' to P1/P1'.
    Ax A; Schaal W; Vrang L; Samuelsson B; Hallberg A; Karlén A
    Bioorg Med Chem; 2005 Feb; 13(3):755-64. PubMed ID: 15653343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D; Sham YY; Vince R
    Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. X-ray structure and conformational dynamics of the HIV-1 protease in complex with the inhibitor SDZ283-910: agreement of time-resolved spectroscopy and molecular dynamics simulations.
    Ringhofer S; Kallen J; Dutzler R; Billich A; Visser AJ; Scholz D; Steinhauser O; Schreiber H; Auer M; Kungl AJ
    J Mol Biol; 1999 Mar; 286(4):1147-59. PubMed ID: 10047488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
    Wei Y; Ma CM; Hattori M
    Eur J Med Chem; 2009 Oct; 44(10):4112-20. PubMed ID: 19493591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR.
    Garg R; Bhhatarai B
    Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
    Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
    J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
    Zhu M; Du XN; Li YG; Zhang GN; Wang JX; Wang YC
    Bioorg Med Chem Lett; 2019 Feb; 29(3):357-361. PubMed ID: 30580917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
    Stranix BR; Lavallée JF; Sévigny G; Yelle J; Perron V; LeBerre N; Herbart D; Wu JJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3459-62. PubMed ID: 16644213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.